

# Binfeng Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6138953/publications.pdf>

Version: 2024-02-01

48  
papers

10,262  
citations

257450  
24  
h-index

243625  
44  
g-index

49  
all docs

49  
docs citations

49  
times ranked

23489  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
3	PD-1 Blockade Boosts Radiofrequency Ablation-Induced Adaptive Immune Responses against Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 1173-1184.	7.0	207
4	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	4.1	193
5	Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. <i>Journal of Immunology</i> , 2015, 194, 438-445.	0.8	185
6	An Increased Abundance of Tumor-Infiltrating Regulatory T Cells Is Correlated with the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e91551.	2.5	169
7	ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. <i>Journal of Neuroscience</i> , 2017, 37, 4692-4704.	3.6	169
8	Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion. <i>Journal of Immunology</i> , 2014, 193, 1525-1530.	0.8	149
9	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	5.9	149
10	B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. <i>Cell Death and Disease</i> , 2019, 10, 308.	6.3	143
11	IL-36 $\beta$ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015, 28, 296-306.	16.8	93
12	PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 2267-2280.	1.6	92
13	Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4529-4538.	7.0	82
14	Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2016, 94, 535-543.	3.9	81
15	ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. <i>Cell Reports</i> , 2018, 23, 1754-1766.	6.4	69
16	Impeded Ned4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis. <i>Cell Reports</i> , 2014, 7, 871-882.	6.4	66
17	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. <i>Immunologic Research</i> , 2011, 50, 269-275.	2.9	64
18	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. <i>Acta Biomaterialia</i> , 2019, 90, 300-313.	8.3	50

#	ARTICLE	IF	CITATIONS
19	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. <i>Scientific Reports</i> , 2020, 10, 14749.	3.3	44
20	Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. <i>Oncotarget</i> , 2020, 9, 1708064.	4.6	33
21	Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. <i>PLoS ONE</i> , 2018, 13, e0193428.	2.5	32
22	The Molecular Mechanisms That Control Function and Death of Effector CD4 <sup>+</sup> T Cells. <i>Immunologic Research</i> , 2006, 36, 275-282.	2.9	30
23	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. <i>Acta Biomaterialia</i> , 2020, 106, 289-300.	8.3	29
24	Targeted codelivery of doxorubicin and IL-36 $\beta$ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 15, 129-141.	3.3	28
25	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. <i>Science Advances</i> , 2021, 7, .	10.3	28
26	Tumor-Derived IL33 Promotes Tissue-Resident CD8 <sup>+</sup> T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1381-1392.	3.4	26
27	IL-36 $\beta$ Promotes CD8 <sup>+</sup> T Cell Activation and Antitumor Immune Responses by Activating mTORC1. <i>Frontiers in Immunology</i> , 2019, 10, 1803.	4.8	23
28	The IL-1 family in tumorigenesis and antitumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 280-295.	9.6	22
29	IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 634.	4.8	21
30	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. <i>Molecular Pharmaceutics</i> , 2018, 15, 5162-5173.	4.6	20
31	Development and application of sensitive, specific, and rapid CRISPR-Cas13 $\alpha$ -based diagnosis. <i>Journal of Medical Virology</i> , 2021, 93, 4198-4204.	5.0	20
32	Autophagy Induction and Autophagic Cell Death in Effector T Cells. <i>Autophagy</i> , 2007, 3, 158-159.	9.1	18
33	A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. <i>Biomaterials</i> , 2021, 270, 120708.	11.4	14
34	Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8 <sup>+</sup> T Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 640224.	3.7	13
35	CD8 <sup>+</sup> T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. <i>Oncology Letters</i> , 2020, 20, 2655-2664.	1.8	13
36	Ginsenoside PPD $\alpha$ 's Antitumor Effect via Down-Regulation of mTOR Revealed by Super-Resolution Imaging. <i>Molecules</i> , 2017, 22, 486.	3.8	12

#	ARTICLE	IF	CITATIONS
37	The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 779865.	3.7	11
38	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. <i>Science Advances</i> , 2021, 7, eabj4226.	10.3	11
39	Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 615-619.	1.9	9
40	High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. <i>Scientific Reports</i> , 2017, 7, 8769.	3.3	7
41	Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 594-602.	5.1	6
42	Chronic Activation of LXR $\alpha$ Sensitizes Mice to Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1123-1139.	4.3	5
43	Differential Requirement of Beclin 1 for Regulating the Balance of Naïve and Activated CD4 <sup>+</sup> T Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 834.	3.7	2
44	An Essential Role of the RNA Editing Enzyme ADAR1 in T Cell Development.. <i>Blood</i> , 2009, 114, 917-917.	1.4	1
45	Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells. <i>Journal of Immunology</i> , 2017, 199, 2713-2720.	0.8	0
46	IL-17 helps autoimmune th1 responses. <i>FASEB Journal</i> , 2008, 22, 1073.24.	0.5	0
47	Gadd45 $\beta$ Is Important for CD8 <sup>+</sup> T Cell Mediated Tumor Surveillance. <i>FASEB Journal</i> , 2008, 22, 1078.10.	0.5	0
48	Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-10.	2.2	0